Fri Feb 21 14:20:00 UTC 2025: ## Hims & Hers Stock Plummets Despite Positive Revenue Projections
**NEW YORK, NY –** Shares of Hims & Hers Health (HIMS) dropped 5.6% Thursday following a mixed assessment from Bank of America analysts. While BofA raised its price target to $21, it maintained an “underperform” rating, prompting investors to sell off the stock.
Hims & Hers has experienced explosive growth, exceeding 600% over the past year, largely due to its semaglutide products, which compete with weight-loss drugs from major pharmaceutical companies. However, BofA analysts express concern over the company’s heavy reliance on this single product line, projecting that GLP-1 sales could comprise over 50% of Hims & Hers’ revenue by Q2 2025. This dependence creates significant risk as larger pharmaceutical companies increase their GLP-1 production, potentially leading to a sharp decline in Hims & Hers’ sales.
Despite BofA’s bearish outlook, the majority of Wall Street analysts predict continued revenue growth for Hims & Hers, with projections of a doubling in size by 2027. However, even optimistic forecasts show relatively low earnings, resulting in a high price-to-earnings ratio, further supporting BofA’s “sell” recommendation. The disparity in analyst opinions highlights the significant uncertainty surrounding Hims & Hers’ long-term prospects.
First Piper 